# A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

> **NCT01732640** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 9 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **RADIATION:** Intensity Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT01732640
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2016-11
- **Final completion:** 2017-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow accrual and high levels of toxicity lead to early termination.
- **Last updated:** 2018-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01732640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01732640, "A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01732640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*